ORALAIR TABLET

国: カナダ

言語: 英語

ソース: Health Canada

即購入

ダウンロード 製品の特徴 (SPC)
02-12-2016

有効成分:

GRASS POLLEN ALLERGEN EXTRACT

から入手可能:

STALLERGENES CANADA INC

ATCコード:

V01AA02

INN(国際名):

GRASS POLLEN

投薬量:

300UNIT

医薬品形態:

TABLET

構図:

GRASS POLLEN ALLERGEN EXTRACT 300UNIT

投与経路:

SUBLINGUAL

パッケージ内のユニット:

28/30/90

処方タイプ:

Prescription

治療領域:

ALLERGENIC EXTRACTS

製品概要:

Active ingredient group (AIG) number: 0153132002; AHFS:

認証ステータス:

APPROVED

承認日:

2015-04-01

製品の特徴

                                _ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
ORALAIR
Grass Pollen Allergen Extract
100 IR and 300 IR Sublingual Tablets
Allergenic Substance
Stallergenes Canada Inc.
1215 North Service Road West, Suite B
Oakville, ON
L6M 2W2
Canada
Date of Preparation:
September 6, 2016
APPROVAL DATE:
NOVEMBER 18, 2016
SUBMISSION CONTROL NO: 192653
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
CLINICAL TRIALS
.....................................
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

製品の特徴 製品の特徴 フランス語 18-11-2016

この製品に関連するアラートを検索

ドキュメントの履歴を表示する